Corcept Initiates MONARCH A Phase 2b Trial Of Its Proprietary Selective Cortisol Modulator Miricorilant In Patients With Non-Alcoholic Steatohepatitis
Portfolio Pulse from Benzinga Newsdesk
Corcept Therapeutics Incorporated (NASDAQ:CORT) has initiated a Phase 2b trial of its proprietary selective cortisol modulator miricorilant in patients with non-alcoholic steatohepatitis (NASH). The trial, named MONARCH, will evaluate the efficacy and safety of miricorilant in adult patients with biopsy-confirmed NASH. The primary endpoint is reduction in liver fat, with NASH resolution and fibrosis improvement as key secondary endpoints.
October 26, 2023 | 8:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corcept Therapeutics has initiated a Phase 2b trial of miricorilant, a drug aimed at treating NASH. This could potentially open a new market for the company if the trial is successful.
The initiation of the Phase 2b trial of miricorilant represents a significant step for Corcept Therapeutics in its efforts to develop a treatment for NASH. If the trial is successful, it could potentially open a new market for the company, which would likely have a positive impact on its stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100